Abstract
Severe aplastic anemia (SAA) appears to be an immunologically mediated disorder that results in deficient and defective hematopoietic stem cells. Both immune suppression and hematopoietic stem cell transplantation provide effective treatment for SAA. Optimal choice between these therapies depends upon a complex interaction of patient age, disease severity, overall patient health, and donor availability. Recent publications provide additional information on the long-term efficacy and toxicity of both treatments. Prospective studies with long-term follow-up are needed to put these and newer treatments in proper perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
